We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . . X close

AI in Pathology Market: Growth, Size, Share, and Trends

Report Code HIT 8721
Published in May, 2025, By MarketsandMarkets™

Choose License Type

AI in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical Workflow), End User (Hospitals, Labs, Pharma/Biotech), & Region - Global Forecast to 2030

icon1
USD 347.4 MN
MARKET SIZE,
icon2
CAGR 26.5%
(-)
icon3
320
REPORT PAGES
icon4
272
MARKET TABLES

OVERVIEW

AI in Pathology Market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The AI in pathology market is projected to reach USD 347.4 million by 2030 from USD 107.4 million in 2025, at a CAGR of 26.5% from 2025 to 2030. The growth of the AI in pathology market is driven by the increasing adoption of digital pathology and AI-enabled telepathology that enable remote slide review, collaboration, and expert consultations among pathologists. These technologies enhance diagnostic accuracy, workflow efficiency, and access to specialized expertise. Additionally, factors such as the rising demand for advanced diagnostic technologies, growing concerns over misdiagnoses, increasing funding programs to improve patient care standards, and a strong focus on cost containment and hospital operational efficiency are further propelling market expansion.

KEY TAKEAWAYS

  • By Region
    The North America AI in pathology market accounted for a 41.0% revenue share of the global market in 2024.
  • By Offering
    By offering, the end to end solutions segment is expected to register the highest CAGR of 26.9%.
  • By Neural Network
    By neural network, the Convolutional Neural Networks (CNNs) segment is projected to grow at the fastest rate from 2025 to 2030.
  • By Function
    By function, the image analysis segment is expected to dominate the market.
  • By Use Case
    By use case, the drug discovery segment will grow the fastest during the forecast period.
  • By End User
    By end user, the pharmaceutical & biopharmaceutical companies segment is expected to dominate the market, growing at the highest CAGR of 27.6%.

The AI in pathology market is witnessing robust growth, driven by the increasing adoption of digital and AI-powered diagnostic solutions that enhance accuracy, efficiency, and collaboration in pathology workflows. Growing demand for AI-enabled image analysis, clinical decision support systems (CDSS), and data management tools is transforming traditional pathology practices into connected, data-driven ecosystems. Key trends shaping the industry include strategic partnerships between AI developers, hospitals, and life sciences companies, advancements in deep learning models such as CNNs, GANs, and RNNs, and integration of telepathology for remote diagnostics and expert consultations. Additionally, ongoing investments in precision medicine, drug discovery applications, and workflow automation are expanding the market’s scope. As healthcare providers increasingly prioritize cost containment, diagnostic standardization, and improved patient outcomes, AI in pathology continues to emerge as a cornerstone of next-generation diagnostic innovation.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on consumers’ business in the AI in pathology market arises from evolving healthcare demands and technological disruptions in diagnostic workflows. Hospitals, reference laboratories, pharmaceutical companies, and research institutions are the primary users of AI-powered pathology solutions, focusing on improving diagnostic accuracy, efficiency, and data-driven decision-making. Shifts toward digital pathology adoption, remote diagnostics, personalized medicine, and stringent regulatory compliance are transforming operational performance and revenue models of end users. These changes are fueling demand for advanced AI-enabled pathology platforms, image analysis tools, and workflow automation solutions, thereby shaping the market’s overall growth trajectory.

AI in Pathology Market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Integration of AI into multiplex imaging
  • Development of CNNs and advanced AI models
RESTRAINTS
Impact
Level
  • Limited AI expertise and varied regulatory guidelines for medical software
  • High cost of digital pathology systems
OPPORTUNITIES
Impact
Level
  • Integration of multi-omics data
  • Increasing demand for personalized medicines
CHALLENGES
Impact
Level
  • Insufficient data for AI algorithms
  • Data privacy and ethical concerns

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver:Integration of AI into multiplex imaging

The integration of AI in multiplex imaging represents a transformative leap in the field of pathology, particularly as digital pathology continues to advance. Multiplex imaging techniques, such as multiplex immunohistochemistry (IHC) and fluorescence imaging, allow the simultaneous visualization of multiple biomarkers in a single tissue sample. This multi-dimensional data presents unparalleled opportunities for understanding complex biological processes, but it also presents challenges due to the sheer volume and complexity of information generated. AI, specifically deep learning algorithms, is instrumental in addressing these challenges by automating the analysis of multiplex imaging data, identifying patterns, and providing insights that may be beyond human recognition.

Restraint: Limited AI expertise and varied regulatory guidelines for medical software

Companies require a workforce with specific skill sets to develop, manage, and implement AI systems. For instance, personnel dealing with AI systems should be aware of cognitive computing, ML and machine intelligence, deep learning, and image recognition. Integrating AI solutions into existing systems is also challenging, requiring extensive data processing to replicate human brain behavior. Even a minor error can result in system failure or adversely affect the desired result. Despite the increasing demand for AI talent, this area has a notable shortage of skilled professionals. A Deloitte survey in 2024 revealed that the AI talent shortage remains a significant challenge across all industries, with 67% of companies struggling to find qualified professionals despite the ongoing demand, even amid economic disruptions. Notably, 23% of mature AI adopters report skill gaps, higher than less mature organizations, indicating they may have a clearer understanding of the skills they need for transformational projects.

Opportunity: Integration of multi-omics data

Integrating multi-omics data encompassing genomics, proteomics, metabolomics, and transcriptomics represents a massive opportunity for AI in the pathology market. By merging these diverse biological datasets, pathologists can obtain a more comprehensive view of disease mechanisms, enabling a deeper understanding of complex health conditions. This holistic approach identifies intricate relationships between different biological layers, which can be crucial in accurately diagnosing diseases and determining the best therapeutic strategies. The integration of multi-omics data allows for robust predictive analytics.

Challenge: Insufficient data for AI algorithms

AI algorithms require large, diverse, and well-annotated datasets for training and validation. However, acquiring such datasets in pathology can be challenging due to data privacy regulations, data fragmentation across multiple healthcare systems, and the need for expert annotations. Ensuring the availability of high-quality data remains a significant challenge for developing accurate and reliable AI models. Most AI systems require high-quality training photos. Ideally, these training images should be ‘labeled’ (i.e., annotated). Aside from the time constraints, human annotations are frequently an expensive impediment in app development. Crowdsourcing may be cheaper and quicker, but it has the potential to introduce noise.

AI in Pathology Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Use of AI-powered IntelliSite Pathology Solution enabling digital slide scanning, workflow orchestration, and remote collaboration. Streamlined digital pathology adoption, faster diagnosis turnaround, improved inter-pathologist collaboration, and scalable hospital network integration.
uPath enterprise software integrating AI image analysis for oncology and hematopathology. Enhanced diagnostic accuracy, automated biomarker quantification, and better alignment with companion diagnostics.
AI-based breast tissue analysis and digital pathology integration for oncology workflows. Increased cancer detection rates, standardized pathology assessments, and improved patient risk stratification.
Use of HALO AI for quantitative image analysis, biomarker scoring, and spatial tissue mapping. Improved reproducibility, scalability for large-scale studies, and faster research-to-clinic transition.
Whole-slide scanners integrated with OptraASSURE AI for automated cancer detection. Cost-effective digital transformation, real-time remote diagnosis, and enhanced slide traceability.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The AI in pathology market ecosystem consists of AI software developers (Philips, Roche, Aiforia, Indica Labs), hardware manufacturers (Hamamatsu, Leica), and end users (hospitals, reference laboratories, pharmaceutical and biopharmaceutical companies). High-resolution scanners and imaging systems digitize pathology slides, which are then analyzed by AI-powered platforms and cloud-based analytics solutions to improve diagnostic accuracy and workflow efficiency. Middleware and cloud providers enable seamless data integration and large-scale processing, while cybersecurity and compliance vendors ensure data privacy and regulatory adherence. End users drive demand for faster, more accurate, and cost-efficient diagnostics, while technology providers deliver advanced AI solutions. Collaboration across the value chain—from software developers to healthcare providers and regulators—is key to driving innovation, interoperability, and market growth.

AI in Pathology Market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

AI in Pathology Market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

AI in Pathology By Offering

Based on the offering, AI in the pathology market is segmented into end-to-end solutions (integration platforms), niche point solutions, technology, and hardware. The end-to-end solutions segment accounted for the largest share of the market in 2024. The large share of this segment can be attributed to the ability of these solutions to provide enhanced interoperability, data sharing, and simplified data sharing & support. The increasing demand for scalable and advanced technology solutions is also a key growth factor.

AI in Pathology By Neural Network

Based on neural networks, the market is segmented into generative adversarial networks (GANs), convolutional neural networks (CNNs), recurrent neural networks (RNNs), and other neural networks. The CNNs segment accounted for the largest share of AI in the pathology market in 2024. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and the high growth rate of this segment can be attributed to the ability of these neural networks to analyze complex visual data, such as pathological images, extract relevant features, and provide accurate diagnoses. These neural networks also help in the localization & segmentation of the regions of interest within images. They can continuously learn and improve over time by leveraging new data & feedback from pathologists.

AI in Pathology By Function

By function, the AI in pathology market is segmented into image analysis, diagnostics, workflow management, data management, predictive analytics, CDSS (Clinical Decision Support System), automated report generation, and quality assurance tools. In 2024, the image analysis segment accounted for the largest share of the market. The large share of the image analysis segment is attributed to the increasing demand for early diagnosis & precision capabilities, the integration of digital pathology, the shortage of skilled pathologists, and the increased demand for personalized and targeted therapies.

AI in Pathology By Use Case

Based on the use case, the AI in pathology market is segmented into drug discovery, disease diagnosis & prognosis, clinical workflow, and training & education. In 2024, the drug discovery segment accounted for the largest share of the market. This segment is also expected to grow at the highest CAGR during the forecast period. The increasing pharmaceutical & biotechnology R&D expenditure; the growth in high-throughput screening & imaging; the rising use of AI algorithms in pathology image analysis for the identification & classification of diseases; and the ability of AI to accelerate the development of new therapeutics to improve diagnostic accuracy, and enhance personalized medicine are the factors expected to contribute to market growth of this segment.

AI in Pathology By End User

Based on end users, the AI in pathology market is segmented into pharmaceutical & biopharmaceutical companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biopharmaceutical companies segment is the largest end user of the market. This segment's large share and high growth rate can be attributed to advancements in drug discovery & development and the growing use of AI in pathology for drug toxicology testing. Biotechnology companies use AI-based digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

REGION

Asia Pacific to be fastest-growing region in global AI in pathology market during forecast period

The Asia Pacific AI in pathology market is expected to register the highest CAGR during the forecast period, market growth in the Asia Pacific can be attributed to government healthcare initiatives and AI policy support, R&D investments by key players and startups, expanding healthcare infrastructure, and hospital digitization.

AI in Pathology Market Region

AI in Pathology Market: COMPANY EVALUATION MATRIX

In the AI in pathology market matrix, Koninklijke Philips N.V. (Star) leads with a strong market share and comprehensive product footprint, driven by its advanced digital pathology and AI-powered diagnostic platforms that enhance workflow efficiency, image analysis accuracy, and remote collaboration in clinical and research settings. OptraScan (Emerging Leader) is gaining recognition with its cost-effective digital pathology scanners and AI-driven image analysis solutions, catering to mid-sized laboratories and healthcare institutions seeking scalable digital transformation. While Philips dominates through its global reach, integrated ecosystem, and continuous innovation in AI diagnostics, OptraScan demonstrates strong potential to advance toward the leaders' quadrant as demand for affordable and accessible AI-enabled pathology solutions continues to grow.

AI in Pathology Market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 87.2 Million
Market Forecast in 2030 (Value) USD 347.4 Million
Growth Rate CAGR of 26.5% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million/Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Offering :
    • end to end solutions
    • niche point solutions
    • technology
    • hardware
    • microscopes
    • scanners
    • storage systems
  • By Neural network:
    • Convolutional neural networks(CNNS)
    • Generative adversarial networks (GANS)
    • Recurrent neural networks (RNNS)
    • Other neural networks
  • By Function:
    • Image analysis
    • Diagnostics
    • Workflow Management
    • Data Management
    • Predictive Analytics
    • CDSS
    • Automated Report Generation
    • Quality Assurance Tools
  • By Use Case:
    • Drug Discovery
    • Disease Diagnosis & Prognosis
    • Clinical Workflow
    • Training & Education
  • By End User:
    • Pharmaceutical & Biopharmaceutical Companies
    • Hospitals & Reference Laboratories
    • Academic & Research Institutes
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: AI in Pathology Market REPORT CONTENT GUIDE

AI in Pathology Market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Landscape Mapping Profiles and market share analysis of leading AI in pathology vendors covering digital pathology platforms, image analysis software, diagnostic workflow automation tools, and AI-driven tissue characterization solutions. Enables benchmarking of AI pathology offerings, identifies innovation gaps in image analytics and automation, supports portfolio enhancement, and informs partnership or acquisition strategies.
Market Entry & Growth Strategy Regional assessment of digital pathology and AI adoption trends, key drivers (e.g., shortage of pathologists, cancer diagnostics modernization), reimbursement dynamics, and competitive landscape across hospitals, diagnostic labs, and research organizations. Reduces market entry risk, accelerates commercialization through tailored regional strategies, ensures alignment with local regulatory and reimbursement frameworks, and supports scaling in high-growth markets.
Technology & Adoption Trends Insights into adoption of AI-powered image analysis, digital slide scanners, cloud-based pathology workflows, and integration with LIS/EHR systems, along with trends in multimodal and precision diagnostics. Guides product development and investment priorities, helps vendors align technology innovation with diagnostic efficiency and precision medicine goals, and identifies emerging use cases and customer segments.

RECENT DEVELOPMENTS

  • February 2024 : Roche Tissue Diagnostics (RTD) collaborated with PathAI to create AI-powered digital pathology algorithms for RTD's companion diagnostics division. These image analysis algorithms are planned to be implemented on the Roche Navify Digital Pathology platform, ensuring smooth integration into pathology labs worldwide.
  • July 2024 : Castile and León, the Spanish regional health authority, partnered with Aiforia Technologies Plc (Finland) for AI-powered diagnostics. This aims to enhance the diagnostic processes in the region's pathology labs, incorporating an image management system from Sectra alongside AI-based image analysis solutions from Aiforia.
  • February 2024 : The US Food and Drug Administration (FDA) approved the Genius Digital Diagnostics System of Hologic Inc. with its AI algorithm features. This system is the first FDA-approved digital cytology solution that integrates deep-learning AI with advanced volumetric imaging technology to detect pre-cancerous lesions and cervical cancer cells.
  • January 2022 :  Aiforia Technologies Plc collaborated with Mayo Clinic to establish AI-powered pathology research support architecture at the Clinic to enable faster results and scalable studies in translational research.
  • COLUMN 'A' SHOULD BE IN TEXT FORMAT AND NOT DATE FORMAT :

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
28
RESEARCH METHODOLOGY
33
EXECUTIVE SUMMARY
47
PREMIUM INSIGHTS
51
MARKET OVERVIEW
55
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Development of CNNs and advanced AI models
    - Integration of AI into multiplex imaging
    - Increasing cases of misdiagnoses in patients
    - Benefits of AI-augmented telepathology
    - Advancements in deep learning & image processing
    RESTRAINTS
    - High cost of digital pathology systems
    - Limited AI expertise and varied regulatory guidelines for medical software
    - Inadequate interoperability issues with legacy systems
    OPPORTUNITIES
    - Increasing demand for personalized medicines
    - Integration of multi-omics data
    - Predictive analytics for disease progression
    CHALLENGES
    - Insufficient data for AI algorithms
    - Data privacy and ethical concerns
    - Challenges associated with interpretability of AI models
  • 5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 INDUSTRY TRENDS
    EVOLUTION OF AI IN PATHOLOGY
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Machine learning (ML) and artificial intelligence (AI)
    - Computer vision
    COMPLEMENTARY TECHNOLOGIES
    - Cloud computing
    ADJACENT TECHNOLOGIES
    - Telepathology
  • 5.8 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATIONS, BY REGION
    - North America
    - Europe
    - Asia Pacific
  • 5.9 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY REGION
    INDICATIVE PRICING ANALYSIS, BY OFFERING
  • 5.10 PORTER’S FIVE FORCES ANALYSIS
    THREAT FROM NEW ENTRANTS
    THREAT FROM SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.13 END USER ANALYSIS
    UNMET NEEDS OF END USERS
    END USER EXPECTATIONS
  • 5.14 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.15 CASE STUDY ANALYSIS
    CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES
    CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS
    CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 BUSINESS MODELS
  • 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
    KEY USE CASES
    AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY
    - Accelerated biomarker discovery and clinical trial optimization
    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Drug discovery & development market
    - Medical imaging & diagnostics market
    USER READINESS AND IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
  • 5.19 TRADE ANALYSIS
    IMPORT SCENARIO
    EXPORT SCENARIO
  • 5.20 US 2025 TARIFF
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    - US
    - Europe
    - Asia Pacific
    IMPACT ON END USE INDUSTRIES
AI IN PATHOLOGY MARKET, BY OFFERING
101
  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
  • 6.3 NICHE POINT SOLUTIONS
    GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
  • 6.4 TECHNOLOGY
    RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET
  • 6.5 HARDWARE
    HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET
  • 6.6 MICROSCOPES
    NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH
  • 6.7 SCANNERS
    IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
  • 6.8 STORAGE SYSTEMS
    NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH
AI IN PATHOLOGY MARKET, BY NEURAL NETWORK
112
  • 7.1 INTRODUCTION
  • 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
    FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
  • 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
    NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
  • 7.4 RECURRENT NEURAL NETWORKS (RNNS)
    NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET
  • 7.5 OTHER NEURAL NETWORKS
AI IN PATHOLOGY MARKET, BY FUNCTION
119
  • 8.1 INTRODUCTION
  • 8.2 IMAGE ANALYSIS
    DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
  • 8.3 DIAGNOSTICS
    RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
  • 8.4 WORKFLOW MANAGEMENT
    OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
  • 8.5 DATA MANAGEMENT
    EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND
  • 8.6 PREDICTIVE ANALYTICS
    GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET
  • 8.7 CDSS
    PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
  • 8.8 AUTOMATED REPORT GENERATION
    INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
  • 8.9 QUALITY ASSURANCE TOOLS
    RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH
AI IN PATHOLOGY MARKET, BY USE CASE
129
  • 9.1 INTRODUCTION
  • 9.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & SELECTION
    - Analysis of molecular and histological data for biomarker discovery to fuel market
    TARGET VALIDATION
    - Increasing demand for precision medicines to drive market
    HIT IDENTIFICATION & PRIORITIZATION
    - Growing requirement for rapid analysis and cost efficiency to fuel uptake
    HIT-TO-LEAD IDENTIFICATION
    - Advancements in ML to support market growth
    LEAD OPTIMIZATION
    - Growing focus on therapeutic efficacy to propel market
    CANDIDATE SELECTION & VALIDATION
    - Critical requirement for regulatory approvals to drive market
  • 9.3 DISEASE DIAGNOSIS & PROGNOSIS
    INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
  • 9.4 CLINICAL WORKFLOW
    STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
  • 9.5 TRAINING & EDUCATION
    UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH
AI IN PATHOLOGY MARKET, BY END USER
143
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
  • 10.3 HOSPITALS & REFERENCE LABORATORIES
    INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND
AI IN PATHOLOGY MARKET, BY REGION
148
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK
    US
    - High healthcare expenditure and improvements in cloud computing platforms to propel market
    CANADA
    - Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK
    UK
    - Increased focus on drug discovery and development to boost demand
    GERMANY
    - Availability of funding for AI initiatives to fuel uptake
    FRANCE
    - Increasing adoption of big data in healthcare computing to fuel uptake
    ITALY
    - Digital transformation and innovation in healthcare to support market growth
    SPAIN
    - Increased workforce shortage to fuel market
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK
    CHINA
    - Rising cases of infectious and chronic diseases to fuel demand
    JAPAN
    - Advanced healthcare infrastructure to propel market
    INDIA
    - Growing focus on healthcare digitization to boost demand
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK
    BRAZIL
    - Strategic investments for AI adoption to support market growth
    MEXICO
    - Growth in pharmaceutical R&D to drive market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK
    GCC COUNTRIES
    - Increasing investments for expansion of technological expertise to support growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
220
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
  • 12.3 REVENUE ANALYSIS, 2020−2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Offering footprint
    - Use case footprint
    - End user footprint
    - Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT/SERVICE LAUNCHES & APPROVALS
    DEALS
    OTHER DEVELOPMENTS
COMPANY PROFILES
242
  • 13.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    HOLOGIC, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AKOYA BIOSCIENCES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AIFORIA TECHNOLOGIES PLC
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    INDICA LABS INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    OPTRASCAN
    - Business overview
    - Products/Services offered
    - Recent developments
    IBEX MEDICAL ANALYTICS LTD.
    - Business overview
    - Products/Services offered
    - Recent developments
    MINDPEAK GMBH
    - Business overview
    - Products/Services offered
    - Recent developments
    TRIBUN HEALTH
    - Business overview
    - Products/Services offered
    - Recent developments
    TECHCYTE, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    DEEP BIO INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    LUMEA INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    VISIOPHARM
    - Business overview
    - Products/Services offered
    - Recent developments
    AETHERAI
    - Business overview
    - Products/Services offered
    - Recent developments
    AIOSYN
    - Business overview
    - Products/Services offered
    - Recent developments
    PAIGE AI, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    PROSCIA, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    PATHAI, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    TEMPUS LABS, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    KONFOONG BIOINFORMATION TECH CO., LTD.
    DOMORE DIAGNOSTICS AS
    QRITIVE
    DEEPATHOLOGY LTD
    4D PATH INC.
APPENDIX
309
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 EXCHANGE RATES, 2021–2024
  • TABLE 2 ROLE OF PLAYERS IN MARKET ECOSYSTEM
  • TABLE 3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 10 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • TABLE 11 IMPACT OF PORTER’S FORCES
  • TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET
  • TABLE 13 KEY PATENTS IN AI IN PATHOLOGY MARKET
  • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 15 KEY BUYING CRITERIA, BY END USER
  • TABLE 16 UNMET NEEDS OF END USERS
  • TABLE 17 AI IN PATHOLOGY MARKET: END USER EXPECTATIONS
  • TABLE 18 LIST OF CONFERENCES AND EVENTS, 2025–2026
  • TABLE 19 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD MILLION)
  • TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 22 TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS
  • TABLE 23 EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT
  • TABLE 24 AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 25 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 26 AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 27 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 28 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 29 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 30 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 31 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 32 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 33 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 34 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 35 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 36 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 37 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS,BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 38 AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 39 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 40 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 41 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 42 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 43 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 44 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 45 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 46 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 47 AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 48 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
  • TABLE 49 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 50 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 51 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 52 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 53 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 54 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 55 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 56 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 57 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 58 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 59 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 60 AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 61 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 62 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 63 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 64 AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 71 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 72 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 73 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 74 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 75 US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 79 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 80 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 85 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 86 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 87 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 88 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 89 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 90 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 91 UK: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 95 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 96 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 100 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 101 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 105 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 106 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 110 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 111 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 115 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 116 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 126 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 127 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 128 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 132 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 133 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 137 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 138 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 148 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 153 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 154 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 158 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 159 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 163 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 164 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
  • TABLE 179 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
  • TABLE 180 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • TABLE 182 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 183 OFFERING FOOTPRINT
  • TABLE 184 USE CASE FOOTPRINT
  • TABLE 185 END USER FOOTPRINT
  • TABLE 186 REGION FOOTPRINT
  • TABLE 187 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 188 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 189 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 190 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 191 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– APRIL 2025
  • TABLE 192 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 193 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 194 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 195 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 196 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 197 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−MARCH 2025
  • TABLE 198 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−MARCH 2025
  • TABLE 199 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 200 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 201 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025
  • TABLE 202 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 203 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
  • TABLE 204 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021−APRIL 2025
  • TABLE 205 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 206 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
  • TABLE 207 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−APRIL 2025
  • TABLE 208 INDICA LABS INC.: COMPANY OVERVIEW
  • TABLE 209 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 210 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025
  • TABLE 211 INDICA LABS INC.: DEALS, JANUARY 2021−APRIL 2025
  • TABLE 212 INDICA LABS INC.: EXPANSIONS, JANUARY 2021–APRIL 2025
  • TABLE 213 OPTRASCAN: COMPANY OVERVIEW
  • TABLE 214 OPTRASCAN: PRODUCTS/SERVICES OFFERED
  • TABLE 215 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 216 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
  • TABLE 217 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 218 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 219 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 220 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 221 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
  • TABLE 222 MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 223 MINDPEAK GMBH: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 224 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 225 TRIBUN HEALTH: COMPANY OVERVIEW
  • TABLE 226 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 227 TRIBUN HEALTH: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 228 TECHCYTE, INC.: COMPANY OVERVIEW
  • TABLE 229 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 230 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 231 TECHCYTE, INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 232 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 233 DEEP BIO INC.: COMPANY OVERVIEW
  • TABLE 234 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 235 DEEP BIO INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 236 LUMEA INC.: COMPANY OVERVIEW
  • TABLE 237 LUMEA INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 238 LUMEA INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 239 VISIOPHARM: COMPANY OVERVIEW
  • TABLE 240 VISIOPHARM: PRODUCTS/SERVICES OFFERED
  • TABLE 241 VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 242 VISIOPHARM: EXPANSIONS, JANUARY 2021– APRIL 2025
  • TABLE 243 AETHERAI: COMPANY OVERVIEW
  • TABLE 244 AETHERAI: PRODUCTS/SERVICES OFFERED
  • TABLE 245 AETHERAI: DEALS, JANUARY 2021– APRIL 2025
  • TABLE 246 AIOSYN: COMPANY OVERVIEW
  • TABLE 247 AIOSYN: PRODUCTS/SERVICES OFFERED
  • TABLE 248 AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 249 AIOSYN: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 250 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 251 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 252 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 253 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021– APRIL 2025
  • TABLE 254 PAIGE AI, INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 255 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 256 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 257 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 258 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 259 PROSCIA, INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 260 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
  • TABLE 261 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 262 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 263 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 264 PATHAI, INC.: DEALS, JANUARY 2021–APRIL 2025
  • TABLE 265 TEMPUS LABS, INC.: COMPANY OVERVIEW
  • TABLE 266 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 267 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
  • TABLE 268 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 269 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
  • TABLE 270 QRITIVE: COMPANY OVERVIEW
  • TABLE 271 DEEPPATH: COMPANY OVERVIEW
  • TABLE 272 4D PATH INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 KEY PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE ESTIMATION PROCESS
  • FIGURE 5 KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 6 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY
  • FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030)
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 16 DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET
  • FIGURE 17 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024
  • FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
  • FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 23 ECOSYSTEM ANALYSIS
  • FIGURE 24 VALUE CHAIN ANALYSIS
  • FIGURE 25 EUROPE: IVDR TIMELINE
  • FIGURE 26 PORTER’S FIVE FORCES
  • FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2017−APRIL 2025
  • FIGURE 28 NUMBER OF PATENT DOCUMENTS, BY JURISDICTION
  • FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2017–APRIL 2025
  • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 31 KEY BUYING CRITERIA, BY END USER
  • FIGURE 32 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
  • FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
  • FIGURE 34 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD)
  • FIGURE 35 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND)
  • FIGURE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION)
  • FIGURE 39 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024)
  • FIGURE 40 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 41 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 42 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN PATHOLOGY VENDORS
  • FIGURE 45 BRAND/PRODUCT COMPARISON
  • FIGURE 46 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 49 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 51 TEMPUS: COMPANY SNAPSHOT (2024)

 

Methodology

This research study involved the extensive use of primary and secondary sources. It analyzes various factors affecting the industry to identify the segmentation, industry trends, key players, the competitive landscape, and key market dynamics.

Secondary Research

This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, whitepapers, annual reports, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the AI in pathology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the AI in pathology market. Primary sources from the demand side included personnel from pharmaceutical & biopharmaceutical companies, research institutes, and hospitals (small, medium-sized, and large hospitals).

A breakdown of the primary respondents is provided below:

AI in Pathology Market

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

Market Size Estimation

The total size of the AI in pathology market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

AI in Pathology Market

Data Triangulation

The size of the AI in pathology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:

  • Revenues for individual companies were gathered from public sources and databases.
  • Shares of leading players were gathered from secondary sources to the extent available. In certain cases, shares of AI in pathology businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength. 
  • Individual shares or revenue estimates were validated through interviews with experts.
  • The total revenue in the AI in pathology market was determined by extrapolating the market share data of major companies.

Market Definition

The AI in pathology market refers to the commercial space where companies develop, market, and provide products and services that incorporate artificial intelligence technologies specifically designed for pathology applications. This market leverages AI algorithms, machine learning techniques, and advanced computational tools to enhance and automate various aspects of the pathology workflow.

Stakeholders

  • Pathologists
  • Suppliers and Distributors of Digital Pathology Equipment
  • AI System and Solution Providers
  • Medical Research and Biopharmaceutical Companies
  • Pharmaceutical Companies and CROs
  • Hospitals and Clinics
  • Laboratories
  • Regulatory Bodies
  • Academic and Medical Research Institutes
  • Universities and Research Organizations
  • Forums, Alliances, and Associations
  • Technology Providers
  • Healthcare Payers

Report Objectives

  • To define, describe, and forecast the AI in pathology market by offering, neural network, function, use case, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the AI in pathology market
  • To benchmark players operating in the AI in pathology market using the Competitive Leadership Mapping framework, which analyzes key market players and start-ups on various parameters within the broad categories of market share/rank and product/service footprint
  • To track and analyze competitive developments such as product launches, expansions, agreements, partnerships, collaborations, product approvals, investments, and acquisitions to strengthen their market presence in the AI in pathology market.

 

Frequently Asked Questions (FAQ)

Which are the top industry players in the global AI in pathology market?

Koninklijke Philips N.V. (Netherlands), F. www Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAl (Taiwan), Aiosyn (Netherlands), Paige Al, Inc. (US), Proscia Inc. (US), PathAl, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US) are the top industry players.

Which offerings have been included in the AI in pathology market report?

This report contains the following AI in pathology offerings:

  • End-to-end Solutions
  • Niche Point Solutions
  • Technology
  • Hardware
    • Scanners
    • Microscopes
    • Storage Systems

 

Which geographical region dominated the global AI in pathology market in 2024?

North America held the largest market share in 2024.

Which end-user segments have been included in the AI in pathology market report?

The report contains the following end-user segments:

  • Pharmaceutical & Biopharmaceutical Companies
  • Hospitals & Reference Laboratories
  • Academic & Research Institutes

 

What is the total CAGR expected to be recorded for the AI in pathology market during 2025–2030?

The CAGR is expected to record a CAGR of 26.5 % from 2025-2030

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Pathology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Growth opportunities and latent adjacency in AI in Pathology Market